This approval strengthens Dupixent's dominance in type 2 inflammation markets and supports future U.S. approval prospects. Traders should monitor the FDA decision on the sBLA for pediatric CSU, which could further expand commercial reach. Despite recent insider selling, the clinical and regulatory momentum supports continued premium valuation.
REGN drugs
REGN drug pipeline →- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● EYLEA HD 4/10 Approved
- 12 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 13 $745.61entry
- T+1 · 7mo ago +1.29%α +0.08% · $755.25
- T+5 · 7mo ago +0.49%α −2.81% · $749.26
- T+20 · 6mo ago −4.81%α −12.54% · $709.73
- T+60 · 4mo ago −9.30%α −18.28% · $676.23
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Regeneron and Sanofi announced European Commission approval of Dupixent for children aged 2 to 11 years with moderate-to-severe chronic spontaneous urticaria (CSU), expanding its label to younger patients. This marks the first targeted therapy for this age group in the EU and strengthens Dupixent's position in type 2 inflammation-driven diseases.
Key Facts
- European Commission approved Dupixent for children 2 to 11 years with CSU who are unresponsive to antihistamines and naïve to anti-IgE therapy.
- Approval based on LIBERTY-CUPID trial program, including extrapolated adult efficacy data and pediatric safety/efficacy from CUPIDKids trial.
- Dupixent is now approved for children under 12 across four chronic type 2 inflammatory diseases.
- U.S. supplemental Biologics License Application (sBLA) for this population is under review.
Financial Impact
Expands Dupixent's eligible patient population in the EU, increasing long-term revenue potential; no immediate revenue figure provided but represents a meaningful lifecycle extension.
Risk Factors
- Regulatory delays or restrictions in other geographies for this indication.
- Competition from biosimilars or alternative therapies in development.
- Safety profile could evolve with broader pediatric use.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272191 |
Track record
53 reports on REGN
11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 16 of 20 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers